1. Medtech Insight
  2. >>Business

JEFHCLON16: Growth Strategies And What's In Store Post-US Election

 
• By Tina Tan

The Jefferies 2016 London Healthcare Conference, the largest health-care-dedicated investor meeting in Europe, took place this week in London. More than 140 pharma, biotech and medtech companies formally presented, and many more attended to meet and connect with investors and potential commercial partners. This article rounds up the best Tweets posted by the Medtech Insight team attending #JEFHCLON16. It includes insights from a panel session on what's in store for health care in the US post-election, as well as company updates from LivaNova, Smith & Nephew, Coloplast, Varian Medical Systems and bioMérieux.

The 2016 Jefferies London Healthcare Conference, now in its seventh year, looks to be the biggest yet, with more than 140 companies across the health-care sector presenting, and many more delegates attending for one-on-one meetings with potential investors and partners.

While the majority of the presenting companies were in the pharma and biotech sectors, a handful of medtech companies, including many that are leaders in their respective fields, provided business...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.